# US 12,480,089 B2 · Antiviral treatment comprising Blis containing probiotic products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,480,089 B2
- Document ID: US12480089B2
- Status: Granted
- Kind: B2
- Application number: 17/916,421
- Filed: 2021-03-31
- Published: 2023-09-28
- Granted: 2025-11-25
- Earliest claimed: 2020-04-03
- Assignees: Blis Technologies Limited
- Applicants: Blis Technologies Limited
- Inventors: John David Francis Hale; John Robert Tagg
- Web page: https://patentgrep.com/patent/US12480089B2

## CPC

- C12N 1/205: Bacterial isolates
- A23L 33/21: Addition of substantially indigestible substances, e.g. dietary fibres
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C12N 1/20: Bacteria; Culture media therefor
- C12R 2001/46: Streptococcus {; Enterococcus; Lactococcus}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

This invention relates to methods of prophylactically or therapeutically treating viral infections particularly in the lower respiratory tract. Treatment of coronavirus infections is particularly contemplated. The invention also relates to the use of BLIS-producing Streptococcus strains, extracts and exudates thereof, and compositions containing same in the prevention, reduction, or treatment of such virus infections.

## Claims

### Claim 1

A method for a prophylactic or therapeutic treatment of a lower respiratory tract (LRT) virus infection in a patient in need thereof, the method comprising administering to said patient an effective amount of a Blis product,
wherein the LRT virus is selected from the group consisting of influenza A, influenza B, respiratory syncytial virus (RSV), and coronavirus, and
wherein the Blis product is selected from the group consisting of S. salivarius strain K12, S. salivarius strain M18, S. salivarius strain DC0010A, S. salivarius strain Glasgow 3, exudates thereof, extracts thereof, and supernatants thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the LRT virus is influenza A H1N1 or H3N2.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the LRT virus is influenza B Brisbane/60/2008.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the LRT virus is RSV A2.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the LRT virus is a coronavirus.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the coronavirus is a human coronavirus selected from the group consisting of SARS-CoV (2003), HCoV NL63 (2004), HKU1 (2005), MERS-CoV (2012), SARS-CoV-2 (2019), and variants thereof.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the coronavirus is SARS-CoV-2 (Covid-19) or a variant thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the Blis product is in the form of a composition which further comprises a pharmaceutically acceptable diluent, carrier and/or excipient.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the composition is in the form of an inhalable composition, spray, nasal spray, lozenge, gum, capsule, powder, melt, food product, confectionary, or chewable.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the composition is in a form for administration via an inhaler, nebuliser, or atomiser.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the composition is in unit dosage form.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method further comprises administering one or more other active agents.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the other active agent(s) are selected from the group consisting of antibodies, vaccines, immune modulators, probiotics, antimalarial compounds, antiviral compounds, antibiotic compounds, anti-inflammatory compounds and polymerase inhibitors.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the antimalarial compounds are selected from the group consisting of chloroquine and hydroxychloroquine.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the antiviral compounds are selected from the group consisting of lopinavir, ritonavir or a combination thereof.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the antibiotic compounds are selected from the group consisting of amikacin, amoxicillin, ampicillin, azithromycin, carbenicillin, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, chloramphenicol, ciprofloxacin, clindamycin, dalacin, dalfopristin, daptomycin, doxycycline, enrofloxacin, ertapenem, erythromycin, gentamicin, marbofloxacin, meropenem, metronidazole, minocycline, moxifloxacin, nafcillin, ofloxacin, oxacillin, penicillin, quinupristin, rifampin, silver sulfadiazine, sulfamethoxazole, teicoplanin, tetracycline, tobramycin, trimethoprim, vancomycin, bacitracin, polymyxin B, and mixtures thereof.

### Claim 17 (depends on 1)

The method according to claim 1 wherein a high dose of S. salivarius is administered to said patient 1 to 4 times a day.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the anti-inflammatory compounds are selected from steroids, immunoglobulin, cytokine blockers, and JAK inhibitors.

### Claim 19 (depends on 13)

The method according to claim 13, wherein the polymerase inhibitors are selected from remdesivir, galidesivir and favipiravir.

### Claim 20 (depends on 13)

The method according to claim 13, wherein the antibodies are selected from bamlanivimab, casirivimab, etesevimab, VIR 7831, REGEN-COV and imdevimab, and combinations thereof.

### Claim 21 (depends on 13)

The method according to claim 13, wherein the vaccines comprise a SARS CoV-2 vaccine.

### Claim 22 (depends on 13)

The method according to claim 13, wherein the immune modulators are selected from budesonide (inhaled), AZD7422, azithromycin, doxycycline, tocilizumab, sarilumab, canakinumab, anakinra, baricitinib, ruxolitinib, acalabrutinib, brensocatib, ravulizumab, gemtuzumab ozogamicin, namilumab, infliximab, adalimumab, otilimab, Medi3506, leronlimab, risankizumab, lenzilumab, and IMU-838.